Gilead Sciences And Terray Therapeutics Have Entered Into A Strategic Collaboration To Discover And Develop Novel, Small Molecule Therapies Across Multiple Targets
Gilead Sciences And Terray Therapeutics Have Entered Into A Strategic Collaboration To Discover And Develop Novel, Small Molecule Therapies Across Multiple Targets
吉利德科學與Terray Therapeutics達成戰略合作，共同發現和開發針對多個靶點的新型小分子療法。
- Gilead and Terray Will Leverage Terray's tNova Drug Discovery Platform to Identify Small Molecule Therapeutics Against Targets of Interest.
- Gilead Has Exclusive Option to Develop and Commercialize Products from the Collaboration.
- Under the terms of the agreement, Terray will utilize the Terray tNova platform to discover and develop small molecule compounds against a set of targets selected by Gilead.
- If Gilead exercises its option to exclusively license the compounds directed to a target, Gilead will be responsible for further development and commercialization activities for products resulting from the collaboration. Terray will receive an upfront payment and is eligible to receive milestone payments associated with the achievement of preclinical, clinical, and sales milestones as well as tiered royalties on net sales of products commercialized by Gilead in connection with the collaboration.
- 吉利德和Terray將利用Terray的tNova藥物發現平台識別針對感興趣靶點的小分子治療藥物。
- 吉利德擁有開發和商業化合作產品的獨佔選擇權。
- 根據協議條款，Terray將利用Terray tNova平台發現和開發針對吉利德選擇的一組靶點的小分子化合物。
- 如果吉利德行使其獨佔許可的選項，針對某一靶點的化合物將由吉利德進一步開發和商業化，Terray將獲得預付款，並有資格根據預臨床、臨床和銷售里程碑的實現獲得階段性付款，以及在吉利德與合作相關產品的淨銷售中獲得分層的版稅。
資訊熱榜
更新時間